Semax and Epitalon at the July 2026 PCAC: What the Day-Two Agenda and Dual June Deadlines Mean for Research Procurement

Key takeaways

• The FDA's Pharmacy Compounding Advisory Committee (PCAC) will review Semax and Epitalon on 24 July 2026, alongside delta sleep-inducing peptide (DSIP/Emideltide), for potential inclusion on the Section 503A Bulk Drug Substances List.
• Requests to make oral presentations to the PCAC must be submitted by 30 June 2026; written comments are accepted through 9 July 2026.
• Simultaneously, the FDA's public comment period on its proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list closes on 29 June 2026 — one day earlier.
• A positive PCAC recommendation would open a licit compounding pathway in the United States for the first time, altering the supplier landscape that UK labs currently draw on.
• Both Semax and Epitalon carry evidence bases that are largely Russian in origin and have not been independently replicated at scale, a point the PCAC will scrutinise directly.

The regulatory context: a concentrated fortnight

The week of 23 June 2026 is shaping up as an unusual concentration of US regulatory deadlines relevant to peptide research procurement. On 29 June, the FDA closes public comment on its proposal — announced on 30 April 2026 and published in the Federal Register on 1 May — to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list. The following day, the window for oral presentation requests to the July PCAC closes.

The two processes are legally distinct — one concerns large-scale 503B outsourcing facilities compounding approved GLP-1 drugs; the other concerns whether novel peptides should be added to the 503A list available to traditional compounding pharmacies — but they arrive almost simultaneously and both carry upstream consequences for research supply chains.

This briefing concentrates on the Day-Two PCAC agenda: Semax and Epitalon (reviewed alongside DSIP/Emideltide).

Why the 503B GLP-1 deadline matters to UK labs

According to FDA Commissioner Marty Makary, "when FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need." The agency reviewed nominations for all three GLP-1 agents and found no demonstrated clinical need for large-scale outsourcing-facility compounding.

If finalised, the rule would prohibit 503B outsourcing facilities from compounding semaglutide, tirzepatide, and liraglutide from bulk substances under any circumstances, regardless of future market conditions. Critically, a formal exclusion would foreclose any future pathway for bulk compounding, even in the event of a new shortage designation.

Patient safety data shaped the FDA's posture throughout the process. As of early 2025, the agency had received more than 455 adverse event reports linked to compounded semaglutide and more than 320 reports associated with compounded tirzepatide, many involving dosing errors from patients self-administering incorrect doses from multidose vials — some of which required hospitalisation.

For UK-based researchers procuring GLP-1 reference standards or analogues from US-sourced suppliers, the closure of the 503B bulk compounding channel will not directly affect purchases of research-use-only (RUO) material; those transactions operate under a separate framework. Procurement managers should nonetheless monitor whether US supplier consolidation — driven by reduced compounding volumes — affects catalogue availability or lot sizing of related materials.

The PCAC Day-Two agenda: Semax, Epitalon, and DSIP

On 24 July 2026, the PCAC will discuss three bulk drug substances for potential inclusion on the 503A Bulks List: Emideltide (delta sleep-inducing peptide, DSIP), Semax, and Epitalon. All three were among the 12 peptides removed from FDA Category 2 on 15 April 2026, opening the pathway for PCAC evaluation. The committee is an advisory body; its recommendations are non-binding, but the FDA generally follows positive recommendations and a negative recommendation often means the substance remains off the list.

The indications the FDA will evaluate are specific and narrower than the broad claims circulating in consumer media:

• Emideltide (DSIP): opioid withdrawal, chronic insomnia, and narcolepsy.
• Semax: cerebral ischaemia, migraine, and trigeminal neuralgia.
• Epitalon: insomnia.

Semax: mechanism, evidence, and regulatory standing

Semax is a synthetic heptapeptide originally developed in Russia, where it has been approved for cerebrovascular and cognitive indications. The FDA review covers cerebral ischaemia, migraine, and trigeminal neuralgia — the neurological applications supported by the compound's Russian clinical literature.

Semax has a long history of use outside the United States for neurological and cognitive conditions. The PCAC will weigh four factors standard to its evaluations: physical and chemical characterisation, safety issues raised by compounding use, available evidence of effectiveness, and historical use in compounding including medical literature references.

The core evidentiary challenge is that the FDA's revised 503A document, published 15 April 2026, removes Semax from Category 2 and schedules it for PCAC review on 24 July 2026, but the bulk of the clinical record originates from Russian-language trials. Independent replication in controlled Western settings remains limited. A positive PCAC recommendation would, for the first time, allow US-licensed 503A compounding pharmacies to prepare Semax legally pursuant to a valid patient-specific prescription — a meaningful shift in the licit supply landscape.

Epitalon: mechanism, evidence, and the scope caveat

Epitalon is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG), developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in the 1980s. It is based on epithalamin, a peptide extract from the pineal gland. The proposed mechanism centres on support of pineal gland function: Epitalon is proposed to normalise melatonin production, particularly in ageing individuals whose melatonin output has declined, alongside proposed telomerase upregulation and antioxidant effects.

A 2025 peer-reviewed study from Brunel University London published in Biogerontology investigated Epitalon's effects on telomere length in human cell lines, examining whether the mechanism involves telomerase upregulation or alternative lengthening of telomeres (ALT) activity. This represents a notable contribution to the Western literature, though it is a cell-line study rather than a clinical trial.

Procurement teams should note two important scope limitations. First, the broader anti-ageing and telomere claims commonly attached to Epitalon in consumer peptide media are not part of the FDA's review scope — the PCAC will evaluate only the insomnia indication. Second, cell-line studies show Epitalon increases telomere length and telomerase activity, but human replication is limited to case reports and small open-label studies. Critically, every prior preclinical and clinical study has been conducted by the Khavinson group in Russia, with no independent confirmation of their results, making the 2025 Brunel cell-line work particularly significant as a first independent data point.

Epitalon is not approved by the FDA, EMA, or other Western regulators and is currently sold as a research compound only.

What a positive recommendation would and would not change

If a peptide is recommended for inclusion by the PCAC and the FDA ultimately adds it to the 503A Bulks List, compounding becomes lawful under Section 503A. However, this would not constitute FDA approval: compounded peptides would still lack formal clinical indication approval, large-scale Phase III trial data, and standardised dosing guidelines. Compounding eligibility and drug approval are legally and practically distinct.

For UK research procurement, the practical consequences of a positive US recommendation are indirect but real:

1. Supply chain legitimacy: A US 503A listing increases the probability that established compounding pharmacies invest in pharmaceutical-grade synthesis infrastructure, raising the average quality standard of commercially available material globally.
2. Supplier consolidation: Regulatory clarity tends to draw well-capitalised suppliers into a market while squeezing out grey-market actors, improving lot-to-lot consistency and Certificate of Analysis (CoA) reliability.
3. MHRA alignment: The MHRA operates independently and a US PCAC recommendation does not alter UK regulatory status. UK labs procuring Semax or Epitalon for research use should continue to verify that material is supplied under a "research use only" designation, with no claims of human therapeutic use attached.

Submission deadlines: practical guidance

For organisations wishing to participate in the PCAC process:

• Oral presentation requests must reach the FDA by 30 June 2026.
• Written comments submitted by 9 July 2026 will be provided directly to the committee.
• All submissions should reference Docket No. FDA-2026-N-2979 and can be filed electronically via regulations.gov.
• The 503B GLP-1 exclusion comment period closes one day earlier, on 29 June 2026, via a separate federal docket referenced in the FDA's April 30 announcement.

UK organisations with relevant scientific data on Semax or Epitalon — particularly those holding independent replication data — may wish to consider whether formal comment is appropriate. The PCAC process is explicitly designed to incorporate nominations supported by published evidence, and the 2025 Brunel telomerase study represents the kind of independent Western data the committee is likely to weight carefully.

This briefing is for research procurement professionals and does not constitute legal or medical advice. Regulatory status in the United Kingdom is governed by the MHRA and is not directly affected by FDA PCAC recommendations.